HK Stock MarketDetailed Quotes
01513 LIVZON PHARMA
- 26.200
- -0.350-1.32%
Market Closed Nov 22 16:08 CST
24.31BMarket Cap10.83P/E (TTM)
26.800High25.950Low864.45KVolume26.800Open26.550Pre Close22.62MTurnover0.28%Turnover Ratio11.27P/E (Static)927.78MShares34.00052wk High1.55P/B8.04BFloat Cap20.86852wk Low1.48Dividend TTM307.05MShs Float36.357Historical High1.480Dividend LFY3.20%Amplitude1.546Historical Low26.172Avg Price100Lot Size5.65%Div YieldTTM5.65%Div Yield LFY
LIVZON PHARMA Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||||
| Earning before tax | ---- | 15.38%1.35B | ---- | -2.96%1.9B | ---- | 5.06%1.17B | ---- | 0.18%1.96B | ---- | -5.28%1.12B |
| Profit adjustment | ||||||||||
| Investment loss (gain) | ---- | 68.30%-15.57M | ---- | -40.14%-61.82M | ---- | -34.08%-49.13M | ---- | 50.78%-44.11M | ---- | -4.38%-36.64M |
| Impairment and provisions: | ---- | -38.68%32.35M | ---- | 164.17%323.1M | ---- | 72.01%52.76M | ---- | 90.17%122.31M | ---- | -17.53%30.67M |
| -Other impairments and provisions | ---- | -85.91%3.21M | ---- | 129.72%13.07M | ---- | 562.83%22.79M | ---- | -24.54%5.69M | ---- | -59.92%3.44M |
| Revaluation surplus: | ---- | -43.33%18.39M | ---- | -65.92%25.65M | ---- | -63.45%32.45M | ---- | 226.89%75.27M | ---- | 355.14%88.78M |
| Asset sale loss (gain): | ---- | -76.71%76.44K | ---- | 119.80%170.44K | ---- | -35.71%328.23K | ---- | 87.77%-860.66K | ---- | 260.99%510.52K |
| -Loss (gain) on sale of property, machinery and equipment | ---- | -76.71%76.44K | ---- | 119.80%170.44K | ---- | -35.71%328.23K | ---- | 87.77%-860.66K | ---- | 260.99%510.52K |
| Depreciation and amortization: | ---- | -33.79%339.81M | ---- | 29.50%887.9M | ---- | 92.31%513.21M | ---- | 45.46%685.63M | ---- | 19.12%266.86M |
| -Amortization of intangible assets | ---- | -90.55%19.95M | ---- | 95.96%294.99M | ---- | 1,784.86%211.16M | ---- | 729.97%150.54M | ---- | 34.48%11.2M |
| -Other depreciation and amortization | ---- | 76.92%65.22M | ---- | 42.84%47.58M | ---- | 166.01%36.86M | ---- | 27.77%33.31M | ---- | 2.27%13.86M |
| Financial expense | ---- | 7.56%48.45M | ---- | 141.07%94.96M | ---- | 97.51%45.05M | ---- | -61.65%39.39M | ---- | -54.14%22.81M |
| Change of operating capital | ||||||||||
| Inventory (increase) decrease | ---- | 123.85%57.93M | ---- | 32.92%-334.42M | ---- | -36.80%-242.89M | ---- | -114.90%-498.57M | ---- | -8,094.48%-177.55M |
| Accounts receivable (increase)decrease | ---- | 2.96%-308.49M | ---- | 170.60%466.29M | ---- | -95.16%-317.89M | ---- | 0.64%-660.45M | ---- | 80.68%-162.89M |
| Accounts payable increase (decrease) | ---- | 197.25%10.49M | ---- | -111.18%-115.71M | ---- | -103.39%-10.79M | ---- | 353.89%1.03B | ---- | 552.56%318.62M |
| Special items of business | ---- | -126.89%-8.1M | ---- | 2.65%65.22M | ---- | 171.25%30.13M | ---- | 17.31%63.54M | ---- | -182.92%-42.29M |
| Adjustment items of business operations | 4.32%2.31B | 28.48%1.54B | 208.30%924.25M | 17.52%3.18B | 19.72%2.21B | -18.49%1.2B | -57.80%299.78M | 46.58%2.71B | 41.57%1.85B | 135.40%1.47B |
| Net cash from operations | 4.32%2.31B | 24.67%1.53B | 208.30%924.25M | 17.18%3.25B | 19.72%2.21B | -13.96%1.23B | -57.80%299.78M | 45.75%2.77B | 41.57%1.85B | 111.34%1.43B |
| Cash flow from investment activities | ||||||||||
| Dividend received - investment | -81.69%12.84M | -73.77%7M | -77.77%5.83M | 11.16%145.27M | 9.28%70.12M | -58.18%26.68M | 284.12%26.24M | 32.84%130.69M | -28.00%64.17M | -0.08%63.81M |
| Sale of fixed assets | -94.30%420.61K | 339.89%233.14K | --201.34K | 388.87%14.46M | 852.19%7.38M | -90.87%53K | ---- | -67.44%2.96M | -89.45%775.17K | -38.17%580.55K |
| Purchase of fixed assets | 26.94%-405.24M | 32.30%-270.18M | -6.29%-155.62M | 12.73%-820.45M | 29.83%-554.64M | 32.65%-399.06M | 27.24%-146.42M | 28.18%-940.15M | 1.99%-790.43M | -22.37%-592.48M |
| Acquisition of subsidiaries | ---- | ---- | ---- | ---22.46M | ---22.46M | ---22.46M | ---12.46M | ---- | ---- | ---- |
| Recovery of cash from investments | 17.00%437.98M | 7.94%404.07M | ---- | --471.56M | --374.33M | --374.33M | --70.03M | ---- | ---- | ---- |
| Cash on investment | -64.83%-671.91M | 10.87%-363.36M | -4,873.46%-307.55M | -18.53%-473.16M | -1,243.62%-407.64M | -1,243.82%-407.69M | 79.62%-6.18M | 49.21%-399.18M | 96.08%-30.34M | 95.92%-30.34M |
| Other items in the investment business | 93.32%-1.4M | 89.60%-931.04K | -105.11%-202.36K | 2.42%-23.6M | -58.97%-21.03M | -111.82%-8.95M | -34.47%3.96M | -739.05%-24.18M | -344.21%-13.23M | -192.75%-4.23M |
| Net cash from investment operations | -13.25%-627.32M | 48.94%-223.17M | -605.48%-457.34M | 42.40%-708.37M | 27.97%-553.93M | 22.31%-437.1M | 70.33%-64.83M | 34.47%-1.23B | 44.00%-769.05M | 46.48%-562.65M |
| Net cash before financing | 1.33%1.68B | 65.38%1.31B | 98.72%466.91M | 64.67%2.54B | 53.72%1.66B | -8.51%790.21M | -52.22%234.96M | 5,967.38%1.54B | 1,686.37%1.08B | 329.53%863.73M |
| Cash flow from financing activities | ||||||||||
| New borrowing | 9.99%3B | 6.88%1.98B | -37.81%642.75M | -1.51%3.66B | -19.57%2.73B | -26.34%1.86B | -38.35%1.03B | 32.63%3.71B | 47.33%3.4B | 108.09%2.52B |
| Refund | -30.65%-3.04B | -72.20%-2.09B | -104.81%-1.22B | -11.44%-3.13B | 10.17%-2.33B | 37.31%-1.21B | 55.11%-595.57M | -37.92%-2.8B | -50.58%-2.59B | -167.62%-1.93B |
| Dividends paid - financing | 11.04%-1.64B | 24.09%-711.94M | 23.58%-23.82M | -19.14%-1.9B | -17.70%-1.84B | 35.54%-937.86M | -84.88%-31.17M | -5.98%-1.59B | -8.07%-1.57B | -6.01%-1.45B |
| Absorb investment income | 312.21%161.75M | 324.93%156.33M | 115.00%79.1M | 81.15%76.53M | 47.62%39.24M | 63.92%36.79M | 73.64%36.79M | -94.71%42.25M | -96.47%26.58M | -96.79%22.44M |
| Other items of the financing business | -7.89%-393.18M | 4.03%-146.93M | -4.69%-132.83M | -360.70%-369.72M | -1,809.63%-364.44M | -1,215.62%-153.1M | -22,260.25%-126.89M | 90.86%-80.25M | 97.57%-19.08M | 98.52%-11.64M |
| Net cash from financing operations | -8.14%-1.91B | -96.57%-805.74M | -306.71%-654.61M | -130.01%-1.66B | -133.41%-1.77B | 52.20%-409.89M | -10.37%316.69M | 11.61%-720.36M | 15.70%-757.59M | 11.63%-857.43M |
| Effect of rate | -164.64%-21.35M | -91.02%2.87M | 97.10%-690.2K | -83.95%20.04M | -74.95%33.03M | -50.12%31.98M | -147.55%-23.82M | 436.17%124.89M | 812.83%131.85M | 390.63%64.1M |
| Net Cash | -110.93%-231.66M | 31.76%501.12M | -134.03%-187.7M | 7.45%883.68M | -134.18%-109.83M | 5,932.87%380.31M | -34.73%551.64M | 204.16%822.45M | 133.24%321.28M | 100.47%6.3M |
| Begining period cash | 8.97%10.98B | 8.97%10.98B | 8.97%10.98B | 10.38%10.07B | 10.38%10.07B | 10.38%10.07B | 10.38%10.07B | -8.31%9.13B | -8.31%9.13B | -8.31%9.13B |
| Cash at the end | 7.28%10.72B | 9.49%11.48B | 1.77%10.79B | 8.97%10.98B | 4.36%10B | 14.02%10.48B | 6.42%10.6B | 10.38%10.07B | 6.82%9.58B | 7.13%9.2B |
| Cash balance analysis | ||||||||||
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | Grant Thornton Certified Public Accountants (Special General Partnership) | -- | -- | -- | Grant Thornton Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
% Chg
No Data